Activist hedge fund Elliott Advisors is tapping six pharma executives and M&A experts to stand for election to the Actelion (ATLN.VX) board, stepping up pressure for major changes at Europe's biggest biotech firm. The New York-based fund, Actelion's largest shareholder, has urged the Swiss group to consider putting itself up for sale after a spate of product setbacks last year. Some analysts, however, were sceptical about the strength of Elliott's candidates and questioned its ability to force through a shake-up.
Source
